

In uncontrolled type 2 diabetes with comorbidities

# Rx *istamet*<sup>TM</sup> **D-XR** 1000

Sitagliptin Phosphate 100mg + Metformin HCl Extended Release 1000mg + Dapagliflozin 10mg Tablets



All round intensification  
to *Live Well*  
with diabetes

**Tight and durable  
glycemic control\***

**Wider protection<sup>§</sup>**

**Hassle-free  
experience<sup>#</sup>**

A trusted companion for your patients to *Live Well* with Diabetes

## *istavel*<sup>®</sup> *istamet*<sup>TM</sup>

Sitagliptin Phosphate tablets IP 25mg, 50mg and 100mg

Sitagliptin Phosphate and Metformin HCl film coated tablets  
50mg/500mg and 50mg/1000mg

## *istamet*<sup>TM</sup> **XR** <sup>500</sup>/<sub>1000</sub>

Sitagliptin Phosphate tablets IP 100mg & Metformin HCl SR Tablets IP 500/1000mg



\*Bailey, C.J., Gross, J.L., Hennicken, D. et al. BMC Med 11, 43 (2013), June 2015 PLoS ONE 10(6):e0129477. <sup>§</sup>N Engl J Med 2019; 380:347-357 Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med 2015;Jun 8. <sup>#</sup>Gian Paolo Fadini et al. Diabetes Obes Metab. 2018 Mar.



In uncontrolled type 2 diabetes,  
with increasing complexities,

To *Live Well*,  
the need for all round effort intensifies

For the use of a registered medical practitioner or a hospital or laboratory only.  
L0033714/8389160




All-round intensification to *Live Well* with diabetes

Rx **istamet<sup>TM</sup> D-XR 1000**


Sitagliptin Phosphate 100mg + Metformin HCl Extended Release 1000mg + Dapagliflozin 10mg Tablets

## Phase III clinical trial demonstrates tighter and durable glycemic control

### More number of patients achieving HbA<sub>1c</sub> goal of <7%\*



### Significant reduction in HbA<sub>1c</sub>\*



\* Data on file HbA<sub>1c</sub>: Glycated hemoglobin

1. D 10mg: Dapagliflozin 10mg, 2. M ER 1000mg: Metformin Extended Release 1000mg, 3. S 100mg: Sitagliptin 100mg, 4. M 1000mg: Metformin 1000mg.